Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
95.40    -0.80 (-0.83%)
Bid:
96.00
Ask:
96.80
Spread: 0.80 (0.833%)
Market Cap: £580.22m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Syncona News

Syncona net asset value falls on "challenging" market, dollar weakness
7 Feb 2023

Syncona net asset value falls on "challenging" market, dollar weakness

(Alliance News) - Syncona Ltd on Tuesday reported a decline in its third quarter net asset value, noting a depreciating US dollar against sterling and...

Syncona NAV falls in Q3
7 Feb 2023

Syncona NAV falls in Q3

(Sharecast News) - Healthcare company Syncona said on Tuesday that net assets had fallen in the three months ended 31 December, principally due to the...

Life Science REIT lets second floor of Rolling Stock Yard in London
25 Jan 2023

Life Science REIT lets second floor of Rolling Stock Yard in London

(Alliance News) - Life Science REIT PLC on Wednesday said it signed an agreement to lease the second floor of its Rolling Stock Yard asset near King's...

Syncona investee Autolus sells more American shares
22 Dec 2022

Syncona investee Autolus sells more American shares

(Sharecast News) - Life science-focussed healthcare company Syncona said on Thursday that its portfolio company Autolus Therapeutics had announced tha...

Syncona portfolio firm hits 70% remission rate goal in leukaemia trial
9 Dec 2022

Syncona portfolio firm hits 70% remission rate goal in leukaemia trial

(Alliance News) - Syncona Ltd on Friday said portfolio company Autolus Therapeutics PLC achieved the primary endpoint in the clinical trial of its tre...

Syncona's Autolus leukemia treatment meets trial endpoint
9 Dec 2022

Syncona's Autolus leukemia treatment meets trial endpoint

(Sharecast News) - Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) ...

Syncona investee Achilles continues to progress cancer trials
6 Dec 2022

Syncona investee Achilles continues to progress cancer trials

(Alliance News) - Syncona Ltd on Tuesday noted the continued positive progress in lung cancer trials by its portfolio company.

Syncona's Achilles says cancer treatment shows promise; seals buy
1 Dec 2022

Syncona's Achilles says cancer treatment shows promise; seals buy

(Alliance News) - Syncona Ltd on Thursday noted a promising safety profile for a cancer therapy concocted by one investee, and separately announced th...